Acute Renal Failure Clinical Trial
OBJECTIVES: I. Determine the maximum tolerated dose and safety of alpha-melanocyte
stimulating hormone (alpha-MSH) in patients with acute renal failure.
II. Determine the safety and pharmacokinetics of alpha-MSH in patients at high risk of acute
renal failure after renal transplantation.
III. Determine the safety and pharmacokinetics of alpha-MSH in patients with established
ischemic acute renal failure.
IV. Determine the effect of alpha-MSH on interleukin-10 pharmacokinetics.
PROTOCOL OUTLINE: This is a dose escalation, double blind, placebo controlled, multicenter
study.
Group 1: Patients are infused with alpha-melanocyte stimulating hormone (alpha-MSH) or
placebo over 5 minutes. A cohort of 5 patients is infused at each dose level of alpha-MSH
until the minimum effective dose (MED) and the maximum tolerated dose (MTD) are determined.
Group 2: Patients receive a single dose of the MED of alpha-MSH IV over 5 minutes at the
time anastomoses are complete. Other patients receive alpha-MSH at the MTD. Cohorts of 5
patients each are treated at the MED and the MTD.
Group 3: Patients receive alpha-MSH as in group 2. Additional dose levels are also tested.
Completion date provided represents the completion date of the grant per OOPD records
;
Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01946113 -
Mineral-Homeostasis in Continuous Renal Replacement Therapy
|
N/A | |
| Withdrawn |
NCT00993733 -
Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care
|
N/A | |
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
| Terminated |
NCT00978354 -
Furosemide in Early Acute Kidney Injury
|
Phase 2/Phase 3 | |
| Completed |
NCT00120263 -
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
|
N/A | |
| Completed |
NCT04799600 -
The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
|
||
| Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
| Completed |
NCT02858531 -
Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
|
||
| Recruiting |
NCT05282732 -
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
|
||
| Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
| Completed |
NCT01979042 -
Urinary Markers for Unilateral Kidney Obstruction
|
N/A | |
| Completed |
NCT01280617 -
Low Dose Thymoglobin in Renal Transplant Patients
|
N/A | |
| Completed |
NCT00780351 -
Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
|
N/A | |
| Completed |
NCT00971971 -
Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients
|
N/A | |
| Completed |
NCT00076219 -
Acute Renal Failure Trial Network (ATN) Study
|
Phase 3 | |
| Recruiting |
NCT04599569 -
Influence of Renal Replacement TherApy on Indirect Calorimetry
|
||
| Completed |
NCT03727204 -
Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
|
||
| Completed |
NCT06005896 -
A Clinical Model for Dialysis Discontinuation in AKI
|
||
| Completed |
NCT03627884 -
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
|
Phase 4 | |
| Completed |
NCT03004950 -
Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
|